Campuzano MG

Language: Spanish
References: 188
Page: 411-435
PDF size: 2297.64 Kb.

ABSTRACT

Like fever and anemia, thrombocytopenia is a sign in which the etiology has to be investigated. Thrombocytopenia can be the result of a defect in platelet production or an increase in platelet destruction. Once thrombocytopenia is detected, the first thing to do is to rule out pseudothrombocytopenia. After the diagnosis of thrombocytopenia is confirmed, the physician, with the aid of the patient’s clinic and diagnostic tests, should be able to determine the etiology before starting any treatment. This module presents the tools to correctly diagnose thrombocytopenia and pseudothrombocytopenia.

REFERENCES

1. Seligsohn U, Coller BS. Classification, clinical manifestations and evaluation of disorders of hemostasis. In William’s hematology, Beutler E, Lichtman MA, Coller BS, Kipps TJ and Seligsohn U. McGraw Hill; New York. 2001; 1471-1478.

2. Kaushansky K, Roth GJ. Megakaryocytes and platelets. In Wintrobe’s clinical hematology, Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F and Glader B. 11th Edition, Lipincott Williams & Wilkins; Philadelphia. 2004; 486-526.

3. Briggs C, Harrison P, Machin SJ. Continuing developments with the automated platelet count. Int J Lab Hematol 2007; 29: 77-91.

4. Teo CP, Kueh YK. Incidence of thrombocytopenia in an acute care hospital. Ann Acad Med Singapore 1989; 18: 379-381.

5. Hanes SD, Quarles DA, Boucher BA. Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother 1997; 31: 285-289.

6. Campuzano-Maya G. Trombocitopenia: más importante que encontrarla es saber porqué se presenta. Medicina & Laboratorio 2007; 13: 111-125.

7. Mhawech P, Saleem A. Inherited giant platelet disorders. Classification and literature review. Am J Clin Pathol 2000; 113: 176-190.

8. López JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998; 91: 4397-4418.

9. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006; 117: 725-738; quiz 739.

10. Lubran MM. Hematologic side effects of drugs. Ann Clin Lab Sci 1989; 19: 114-121.

11. Pedersen-Bjergaard U, Andersen M, Hansen PB. Drugspecific characteristics of thrombocytopenia caused by noncytotoxic drugs. Eur J Clin Pharmacol 1998; 54: 701-706.

12. Aster RH. Can drugs cause autoimmune thrombocytopenic purpura? Semin Hematol 2000; 37: 229-238.

13. Stubner S, Grohmann R, Engel R, Bandelow B, Ludwig WD, Wagner G, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004; 37 Suppl 1: S70-78.

14. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817.

15. Daneschvar HL, Daw H. Heparin-induced thrombocytopenia (an overview). Int J Clin Pract 2007; 61: 130-137.

16. Bodensteiner DC, Doolittle GC. Adverse haematological complications of anticancer drugs. Clinical presentation, management and avoidance. Drug Saf 1993; 8: 213-224.

17. Lim S, Boughton BJ, Bareford D. Thrombocytopenia following routine blood transfusion: micro-aggregate blood filters prevent worsening thrombocytopenia in patients with low platelet counts. Vox Sang 1989; 56: 40-41.

18. www.ctep.cancer.gov/reporting/ctc.html.

19. Sekhon SS, Roy V. Thrombocytopenia in adults: A practical approach to evaluation and management. South Med J 2006; 99: 491-498; quiz 499-500, 533.

20. Marwick C. Platelet volume/count relationship aids thrombocytopenia prognosis. Jama 1983; 249: 2863-2864.

21. George JN, Rizvi MA. Thrombocytopenia. In William’s haematology, Beutler E, Lichtman MA, Coller BS, Kipps TJ and Seligsohn U. 6th ed, McGraw-Hill; New York. 2001; 1495-1539.

22. Onder O, Weinstein A, Hoyer LW. Pseudothrombocytopenia caused by platelet agglutinins that are reactive in blood anticoagulated with chelating agents. Blood 1980; 56: 177-182.

23. Payne BA, Pierre RV. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984; 59: 123-125.

24. Campuzano-Maya G. Editorial: Trombocitopenia: una materia pendiente. Medicina & Laboratorio 2007; 13: 109-110.

25. Easton JA, Fessas C. The incidence of Dohle bodies in various diseases and their association with thrombocytopenia. Br J Haematol 1966; 12: 54-60.

26. Mant MJ, Doery JC, Gauldie J, Sims H. Pseudothrombocytopenia due to platelet aggregation and degranulation in blood collected in EDTA. Scand J Haematol 1975; 15: 161-170.

27. García-Suárez J, Merino JL, Rodríguez M, Velasco A, Moreno MC. Pseudotrombocitopenia: incidencia, causas y métodos de detección. Sangre (Barc) 1991; 36: 197-200.

28. Silvestri F, Virgolini L, Savignano C, Zaja F, Velisig M, Baccarani M. Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. Vox Sang 1995; 68: 35-39.

29. Berkman N, Michaeli Y, Or R, Eldor A. EDTA-dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature. Am J Hematol 1991; 36: 195-201.

30. Lombarts AJ, Zijlstra JJ, Peters RH, Thomasson CG, Franck PF. Accurate platelet counting in an insidious case of pseudothrombocytopenia. Clin Chem Lab Med 1999; 37: 1063-1066.

31. van der Meer W, Allebes W, Simon A, van Berkel Y, de Keijzer MH. Pseudothrombocytopenia: a report of a new method to count platelets in a patient with EDTA- and temperature-independent antibodies of the IgM type. Eur J Haematol 2002; 69: 243-247.

32. Thompson CB, Love DG, Quinn PG, Valeri CR. Platelet size does not correlate with platelet age. Blood 1983; 62: 487-494.

33. Levin J, Bessman JD. The inverse relation between platelet volume and platelet number. Abnormalities in hematologic disease and evidence that platelet size does not correlate with platelet age. J Lab Clin Med 1983; 101: 295-307.

34. Threatte GA, Adrados C, Ebbe S, Brecher G. Mean platelet volume: the need for a reference method. Am J Clin Pathol 1984; 81: 769-772.

35. Lippi U, Schinella M, Modena N, Nicoli M. Unpredictable effects of K3 EDTA on mean platelet volume. Am J Clin Pathol 1987; 87: 391-393.

36. O’Malley T, Ludlam CA, Fox KA, Elton RA. Measurement of platelet volume using a variety of different anticoagulant and antiplatelet mixtures. Blood Coagul Fibrinolysis 1996; 7: 431-436.

37. Gene LG, Asselta A. Uso del mezclador vortex para disolver agregados plaquetarios. Medicina & Laboratorio 1998; 8: 33-37.

38. Bizzaro N. EDTA-dependent pseudothrombocytopenia: a clinical and epidemiological study of 112 cases, with 10-year follow-up. Am J Hematol 1995; 50: 103-109.

39. Kjeldsberg CR, Swanson J. Platelet satellitism. Blood 1974; 43: 831-836.

40. Cohen AM, Lewinski UH, Klein B, Djaldetti M. Satellitism of Platelets to Monocytes. Acta Haematol 1980; 64: 61-64.

41. Fiorin F, Steffan A, Pradella P, Bizzaro N, Potenza R, De Angelis V. IgG platelet antibodies in EDTA-dependent pseudothrombocytopenia bind to platelet membrane glycoprotein IIb. Am J Clin Pathol 1998; 110: 178-183.

42. Español I, Muñiz-Díaz E, Domingo-Claros A. The irreplaceable image: Platelet satellitism to granulated lymphocytes. Haematologica 2000; 85: 1322.

43. Lazo-Langner A, Piedras J, Romero-Lagarza P, Lome-Maldonado C, Sánchez-Guerrero J, López-Karpovitch X. Platelet satellitism, spurious neutropenia, and cutaneous vasculitis: casual or causal association? Am J Hematol 2002; 70: 246-249.

44. McGregor DH, Davis JW, Liu PI, Gates E, Poindexter AR. Platelet satellitism: experimental studies. Lab Invest 1980; 42: 343-355.

45. Cesca C, Ben-Ezra J, Riley RS. Platelet satellitism as presenting finding in mantle cell lymphoma. A case report. Am J Clin Pathol 2001; 115: 567-570.

46. Mori M, Kudo H, Yoshitake S, Ito K, Shinguu C, Noguchi T. Transient EDTA-dependent pseudothrombocytopenia in a patient with sepsis. Intensive Care Med 2000; 26: 218-220.

47. Hosseinzadeh M, Kumar PV, Rahemi M. Platelet satellitism in lupus erythematosus resolving after treatment. Acta Haematol 2006; 115: 131-132.

48. Bizzaro N, Brandalise M. EDTA-dependent pseudothrombocytopenia. Association with antiplatelet and antiphospholipid antibodies. Am J Clin Pathol 1995; 103: 103-107.

49. Matarazzo M, Conturso V, Di Martino M, Chiurazzi F, Guida G, Morante R. EDTA-dependent pseudothrombocytopenia in a case of liver cirrhosis. Panminerva Med 2000; 42: 155-157.

50. Solanki DL, Blackburn BC. Spurious thrombocytopenia during pregnancy. Obstet Gynecol 1985; 65: 14S-17S.

51. Bizzaro N, Fiorin F. Coexistence of erythrocyte agglutination and EDTA-dependent platelet clumping in a patient with thymoma and plasmocytoma. Arch Pathol Lab Med 1999; 123: 159-162.

52. Kozak M, Dovc T, Rozman P, Blinc A. A case of pseudothrombocytopenia after infusion of abciximab in vivo and anticoagulant-independent platelet clumping after rechallenge with abciximab in vitro. Wien Klin Wochenschr 2000; 112: 138-141.

53. Sane DC, Damaraju LV, Topol EJ, Cabot CF, Mascelli MA, Harrington RA, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000; 36: 75-83.

54. Wool RL, Coleman TA, Hamill RL. Abciximab-associated pseudothrombocytopenia. Am J Med 2002; 113: 697-698.

55. Savage RA. Pseudoleukocytosis due to EDTA-induced platelet clumping. Am J Clin Pathol 1984; 81: 317-322.

56. Lombarts AJ, de Kieviet W. Recognition and prevention of pseudothrombocytopenia and concomitant pseudoleukocytosis. Am J Clin Pathol 1988; 89: 634-639.

57. Schrezenmeier H, Muller H, Gunsilius E, Heimpel H, Seifried E. Anticoagulant-induced pseudothrombocytopenia and pseudoleucocytosis. Thromb Haemost 1995; 73: 506-513.

58. Lindsay RM, Koens F, Linton AL. An evaluation of the Coulter thrombocounter in counting platelets before and after contact with foreign surfaces and its use in tests of platelet retention. J Lab Clin Med 1975; 86: 863-872.

59. Kjeldsberg CR, Hershgold EJ. Spurious thrombocytopenia. Jama 1974; 227: 628-630.

60. Nicholls PD. Erroneous platelet counts on the Coulter Model S Plus counter after correction for hyperlipaemia. Med Lab Sci 1983; 40: 69-71.

61. Carrascosa M, Perez-Castrillon JL, Pascual F, Olalla JI, Valle R. Pernicious anemia presenting with acute generalized thrombocytopenic purpura. Am J Hematol 1995; 48: 125.

62. Junca J, Flores A, Granada ML, Jimenez O, Sancho JM. The relationship between idiopathic thrombocytopenic purpura and pernicious anaemia. Br J Haematol 2000; 111: 513-516.

63. Benjilali L, Tazi-Mezalek Z, Harmouche H, Lebbar K, Aouni M, Adnaoui M, et al. Pernicious anemia in a young man with systemic lupus erythematosus. Lupus 2007; 16: 827-829.

64. Hirayama Y, Sakamaki S, Matsunaga T, Kuga T, Kuroda H, Kusakabe T, et al. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. Blood 1998; 92: 46-52.

65. Young NS, Maciejewski JP. Aplastic anemia. In Hematology. Basic principles and practice, Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al. 4th edition, Elseiver, Inc; Philadelphia, Pennsylvania. 2005; 381-417.

66. Sleijfer DT, Mulder NH, Nieweg HO, Anders GJ, Gouw WL. Acquired pancytopenia in relatives of patients with aplastic anaemia. Acta Med Scand 1980; 207: 397-402.

67. Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med 1951; 87: 48-65.

68. Berg SL, Steuber CP, Poplack DG, 1155-1162. Clinical manifestations of acute lymphoblastic leukemia. In Hematology. Basic principles and practice, Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al. 4th edition, Elseiver, Inc; Philadelphia, Pennsylvania. 2005; 1155-1162.

69. Miller KB, Daoust PR. Clinical manifestations of acute myeloid leukemia. In Hematology. Basic principles and practice, Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al. 4th edition, Elseiver, Inc; Philadelphia, Pennsylvania. 2005; 1071-1097.

70. Patel DV, Rai KR. Chronic lymphocytic leukemia. In Hematology. Basic principles and practice, Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al. 4th edition, Elseiver, Inc; Philadelphia, Pennsylvania. 2005; 1437-1454.

71. De Angelo DJ, R.M. S. Myelodysplastic syndromes: Biology and treatment. In Hematology. Basic principles and practice, Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al. 4th edition, Elseiver, Inc; Philadelphia, Pennsylvania. 2005; 1195-1208.

72. Zakarija A, Peterson LC, Tallman MS. Hairy cell leukemia. In Hematology. Basic principles and practice, Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al. 4th edition, Elseiver, Inc; Philadelphia, Pennsylvania. 2005; 1455-1465.

73. Kappers-Klunne MC, van Vliet HH. IgM and IgG platelet antibodies in a case of infectious mononucleosis and severe thrombocytopenia. Scand J Haematol 1984; 32: 145-148.

74. Liebman HA, Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol 2007; 14: 557-573.

75. Ananworanich J, Phanuphak N, Nuesch R, Apateerapong W, Rojnuckarin P, Ubolyam S, et al. Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection. Clin Infect Dis 2003; 37: 723-725.

76. Pizarro PR, Aguad RL, Castro GJ. Trombocitopenia grave e infección por virus de inmunodeficiencia humana. Comunicación de dos casos y revisión de la literatura. Rev Chilena Infectol 2007; 24: 63-67.

77. Laboratorio Clínico Hematológico. Manual de procedimientos. 2007, Medellín, Colombia.

78. ICSH. Recommended methods for the visual determination of white cell and platelet counts. 1988, WHO LAB 88, 3. 1988;

79. Harrison P, Horton A, Grant D, Briggs C, MacHin S. Immunoplatelet counting: a proposed new reference procedure. Br J Haematol 2000; 108: 228-235.

80. Nosanchuk JS, D’Souza JP, Mudholkar GS, Lin CC, Verno M, Buchanan B. A comparative study of five commercial reagents for the Coulter Model S: a proposed method for reagent evaluation. Arch Pathol Lab Med 1978; 102: 258-262.

81. Sociedad Colombiana de Patología Clínica. Manual de Codificación, Nomenclatura, Nivelación y Valores de Exámenes de laboratorio Clínico. Edimeco S.A., Medellín, Colombia. 2007, 1-100.

82. Van den Bossche J, Devreese K, Malfait R, Van de Vyvere M, Wauters A, Neeis H, et al. Reference intervals for a complete blood count determined on different automated haematology analysers: Abx Pentra 120 Retic, Coulter Gen-S, Sysmex SE 9500, Abbott Cell Dyn 4000 and Bayer Advia 120. Clin Chem Lab Med 2002; 40: 69-73.

83. Langford K, Luchtman-Jones L, Miller R, Walck D. Performance evaluation of the Sysmex XT-2000i automated hematology analyzer. Lab Hematol 2003; 9: 29-37.

84. Nakul-Aquaronne D, Sudaka-Sammarcelli I, Ferrero-Vacher C, Starck B, Bayle J. Evaluation of the Sysmex Xe-2100 hematology analyzer in hospital use. J Clin Lab Anal 2003; 17: 113-123.

85. Briggs C, Kunka S, Machin SJ. The most accurate platelet count on the Sysmex XE-2100. Optical or impedance? Clin Lab Haematol 2004; 26: 157-158.

86. Stanworth SJ, Denton K, Monteath J, Patton WN. Automated counting of platelets on the Bayer ADVIA 120 analyser. Clin Lab Haematol 1999; 21: 113-117.

87. Picard F, Gicquel C, Marnet L, Guesnu M, Levy JP. Preliminary evaluation of the new hematology analyzer COULTER GEN-S in a university hospital. Clin Chem Lab Med 1999; 37: 681-686.

88. Grimaldi E, Scopacasa F. Evaluation of the Abbott CELLDYN 4000 hematology analyzer. Am J Clin Pathol 2000; 113: 497-505.

89. Peng L, Gao X, Jiang H, Peng Z, Su J. Laboratory evaluation of the Sysmex SE-9500 automated haematology analyser. Clin Lab Haematol 2001; 23: 237-242.

90. Sandhaus LM, Osei ES, Agrawal NN, Dillman CA, Meyerson HJ. Platelet counting by the coulter LH 750, sysmex XE 2100, and advia 120: a comparative analysis using the RBC/platelet ratio reference method. Am J Clin Pathol 2002; 118: 235-241.

91. Harris N, Jou JM, Devoto G, Lotz J, Pappas J, Wranovics D, et al. Performance evaluation of the ADVIA 2120 hematology analyzer: an international multicenter clinical trial. Lab Hematol 2005; 11: 62-70.

92. Johannessen B, Roemer B, Flatmoen L, Just T, Aarsand AK, Scott CS. Implementation of monoclonal antibody fluorescence on the Abbott CELL-DYN Sapphire haematology analyser: evaluation of lymphoid, myeloid and platelet markers. Clin Lab Haematol 2006; 28: 84-96.

93. Threatte GA. Usefulness of the mean platelet volume. Clin Lab Med 1993; 13: 937-950.

94. Jackson SR, Carter JM. Platelet volume: laboratory measurement and clinical application. Blood Rev 1993; 7: 104-113.

95. Campuzano-Maya G. El hemograma electrónico. Laboratorio Al Día 1995; 5: 28-41.

96. Campuzano-Maya G. El hemograma. Medicina & Laboratorio 1998; 8: 19-32.

97. Trowbridge EA, Martin JF. The platelet volume distribution: a signature of the prethrombotic state in coronary heart disease? Thromb Haemost 1987; 58: 714-717.

98. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157-161.

99. Wiwanitkit V. Plateletcrit, mean platelet volume, platelet distribution width: its expected values and correlation with parallel red blood cell parameters. Clin Appl Thromb Hemost 2004; 10: 175-178.

100. Kaito K, Otsubo H, Usui N, Yoshida M, Tanno J, Kurihara E, et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Haematol 2005; 128: 698-702.

101. Bessman JD, Gardner FH. Platelet size in thrombocytopenia due to sepsis. Surg Gynecol Obstet 1983; 156: 177-180.

102. Bessman JD, Gilmer PR, Gardner FH. Use of mean platelet volume improves detection of platelet disorders. Blood Cells 1985; 11: 127-135.

103. Macchi I, Chamlian V, Sadoun A, Le Dirach A, Guilhot J, Guilhot F, et al. Comparison of reticulated platelet count and mean platelet volume determination in the evaluation of bone marrow recovery after aplastic chemotherapy. Eur J Haematol 2002; 69: 152-157.

104. Bessman JD. The relation of megakaryocyte ploidy to platelet volume. Am J Hematol 1984; 16: 161-170.

105. Karpatkin S, Freedman ML. Hypersplenic thrombocytopenia differentiated from increased peripheral destruction by platelet volume. Ann Intern Med 1978; 89: 200-203.

106. Giles C. The platelet count and mean platelet volume. Br J Haematol 1981; 48: 31-37.

107. Osselaer JC, Jamart J, Scheiff JM. Platelet distribution width for differential diagnosis of thrombocytosis. Clin Chem 1997; 43: 1072-1076.

108. Bessman JD, Gilmer PR, Jr., Gardner FH. Improved classification of anemias by MCV and RDW. Am J Clin Pathol 1983; 80: 322-326.

109. Nelson RB, 3rd, Kehl D. Electronically determined platelet indices in thrombocytopenic patients. Cancer 1981; 48: 954-956.

110. Bessman JD, Williams LJ, Gilmer PR, Jr. Platelet size in health and hematologic disease. Am J Clin Pathol 1982; 78: 150-153.

111. Ingram M, Coopersmith A. Reticulated platelets following acute blood loss. Br J Haematol 1969; 17: 225-229.

112. Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990; 75: 116-121.

113. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CP, Hillman RS. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992; 98: 637-646.

114. Richards EM, Baglin TP. Quantitation of reticulated platelets: methodology and clinical application. Br J Haematol 1995; 91: 445-451.

115. O’Malley CJ, Rasko JE, Basser RL, McGrath KM, Cebon J, Grigg AP, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996; 88: 3288-3298.

116. Nakamura T, Uchiyama S, Yamazaki M, Okubo K, Takakuwa Y, Iwata M. Flow cytometric analysis of reticulated platelets in patients with ischemic stroke. Thromb Res 2002; 106: 171-177.

117. McCabe DJ, Harrison P, Sidhu PS, Brown MM, Machin SJ. Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol 2004; 126: 861-869.

118. Lakkis N, Dokainish H, Abuzahra M, Tsyboulev V, Jorgensen J, De Leon AP, et al. Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 2004; 44: 2091-2093.

119. Zucker ML, Murphy CA, Rachel JM, Martinez GA, Abhyankar S, McGuirk JP, et al. Immature platelet fraction as a predictor of platelet recovery following hematopoietic progenitor cell transplantation. Lab Hematol 2006; 12: 125-130.

120. Takami A, Shibayama M, Orito M, Omote M, Okumura H, Yamashita T, et al. Immature platelet fraction for prediction of platelet engraftment after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 501-507.

121. Wang C, Smith BR, Ault KA, Rinder HM. Reticulated platelets predict platelet count recovery following chemotherapy. Transfusion 2002; 42: 368-374.

122. Stohlawetz P, Stiegler G, Knobl P, Hocker P, Panzer S. The rise of reticulated platelets after intensive chemotherapy for AML reduces the need for platelet transfusions. Ann Hematol 1999; 78: 271-273.

123. Koike Y, Yoneyama A, Shirai J, Ishida T, Shoda E, Miyazaki K, et al. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost 1998; 79: 1106-1110.

124. Briggs C, Kunka S, Hart D, Oguni S, Machin SJ. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 2004; 126: 93-99.

125. Abe Y, Wada H, Tomatsu H, Sakaguchi A, Nishioka J, Yabu Y, et al. A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF). Thromb Res 2006; 118: 463-469.

126. Kickler TS, Oguni S, Borowitz MJ. A clinical evaluation of high fluorescent platelet fraction percentage in thrombocytopenia. Am J Clin Pathol 2006; 125: 282-287.

127. Brugnara C, Lux SE. Introduction to anemias. In Blood: principles and practice of hematology, Handin RI, Lux SE and Stossel TP. 2th edition, Lippincott Williams & Wilkins Company; Philadelphia, PA, USA. 2003; 1346-1360.

128. Briggs C, Hart D, Kunka S, Oguni S, Machin SJ. Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation. Transfus Med 2006; 16: 101-109.

129. Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007; 109: 1705-1714.

130. Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol Oncol Clin North Am 2007; 21: 743-759, vii.

131. Campuzano-Maya G. Proof of an association between Helicobacter pylori and idiopathic thrombocytopenic purpura in Latin America. Helicobacter 2007; 12: 265-273.

132. Ziakas PD, Routsias JG, Giannouli S, Tasidou A, Tzioufas AG, Voulgarelis M. Suspects in the tale of lupusassociated thrombocytopenia. Clin Exp Immunol 2006; 145: 71-80.

133. Fernandez M, Alarcon GS, Apte M, Andrade RM, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum 2007; 56: 614-621.

134. Hardaway RE. Disseminated intravascular coagulation in shock. Thromb Diath Haemorrh Suppl 1969; 36: 159-170.

135. Sarode R, Gottschall JL, Aster RH, McFarland JG. Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol 1997; 54: 102-107.

136. Harker LA. Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol 1998; 35: 241-252.

137. Fontana S, Kremer Hovinga JA, Lammle B, Mansouri Taleghani B. Treatment of thrombotic thrombocytopenic purpura. Vox Sang 2006; 90: 245-254.

138. Elliott MA, Nichols WL. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mayo Clin Proc 2001; 76: 1154-1162.

139. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 2003; 127: 834-839.

140. Peck-Radosavljevic M. Hypersplenism. Eur J Gastroenterol Hepatol 2001; 13: 317-323.

141. Brown KA. Peripheral blood smears: preparation and staining are still important. Clin Lab Sci 1990; 3: 311-312.

142. Breuer GS, Raveh D, Rudensky B, Rosenberg R, Ruchlemer R, Halevy J. Remember the blood smear: a clinical laboratory vignette. Isr Med Assoc J 2002; 4: 1089-1090.

143. Bain BJ. Diagnosis from the blood smear. N Engl J Med 2005; 353: 498-507.

144. Campuzano-Maya G. Editorial: Los contadores de células: son excelentes pero no son perfectos. Medicina & Laboratorio 2005; 11: 309-310.

145. Campuzano-Maya G. Alteraciones del hemograma relacionadas con los contadores de células. Medicina & Laboratorio 2005; 11: 363-384.

146. Lindenbaum J, Nath BJ. Megaloblastic anaemia and neutrophil hypersegmentation. Br J Haematol 1980; 44: 511-513.

147. Campuzano-Maya G. Anemia perniciosa. Medicina & Laboratorio 1997; 7: 679-694.

148. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med 1997; 337: 1441-1448.

149. Toh BH, Alderuccio F. Pernicious anaemia. Autoimmunity 2004; 37: 357-361.

150. Bick RL. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost 1985; 11: 249-280.

151. Perkins SL. Examination of the blood and bone marrow. In Wintrobe’s clinical hematology, Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F and Glader B. 11th Edition, Lipincott Williams & Wilkins; Philadelphia. 2004; 16-34.

152. Makoni SN, Laber DA. Clinical spectrum of myelophthisis in cancer patients. Am J Hematol 2004; 76: 92-93.

153. Chang JC, Naqvi T. Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer. Oncologist 2003; 8: 375-380.

154. Bodem CR, Hamory BH, Taylor HM, Kleopfer L. Granulomatous bone marrow disease. A review of the literature and clinicopathologic analysis of 58 cases. Medicine (Baltimore) 1983; 62: 372-383.

155. Hakawi AM, Alrajhi AA. Tuberculosis of the bone marrow: clinico-pathological study of 22 cases from Saudi Arabia. Int J Tuberc Lung Dis 2006; 10: 1041-1044.

156. Levy TM, Blundell E, Slade R, Burton P, Hows J. Diagnosis of sarcoidosis by bone marrow trephine biopsy. Br J Haematol 1993; 84: 179-181.

157. Yanardag H, Pamuk GE, Karayel T, Demirci S. Bone marrow involvement in sarcoidosis: an analysis of 50 bone marrow samples. Haematologia (Budap) 2002; 32: 419-425.

158. Blair S, Álvarez G, Echeverri M, Campuzano-Maya G. Anemia, trombocitopenia y malaria. Biomédica 1997; 17: 206-207.

159. Ali N, Anwar M, Ayyub M, Nadeem M, Ejaz A, Qureshi AH, et al. Hematological evaluation of splenomegaly. J Coll Physicians Surg Pak 2004; 14: 404-406.

160. Kunishima S, Matsushita T, Kojima T, Amemiya N, Choi YM, Hosaka N, et al. Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions. J Hum Genet 2001; 46: 722-729.

161. Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003; 82: 203-215.

162. Noris P, Spedini P, Belletti S, Magrini U, Balduini CL. Thrombocytopenia, giant platelets, and leukocyte inclusion bodies (May-Hegglin anomaly): clinical and laboratory findings. Am J Med 1998; 104: 355-360.

163. Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001; 69: 1033-1045.

164. Kunishima S, Kojima T, Matsushita T, Tanaka T, Tsurusawa M, Furukawa Y, et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood 2001; 97: 1147-1149.

165. Chiang M, Fleming M. The pseudo-Pelger-Huët anomaly in pyoderma gangrenosum associated with myelodysplastic syndrome. Am J Dermatopathol 2007; 29: 293-295.

166. Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2: 1013-1015.

167. Breederveld K, van Royen EA, Ten Cate JW. Severe factor V deficiency with prolonged bleeding time. Thromb Diath Haemorrh 1974; 32: 538-548.

168. Evensen SA, Myhre L, Stormorken H. Haemostatic studies in osteogenesis imperfecta. Scand J Haematol 1984; 33: 177-179.

169. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16: 1-20.

170. Campuzano-Maya G. Estudio de la medula ósea. Laboratorio Al Día 1995; 5: 295-311.

171. Ryan DH. Examination of the marrow. In William’s haematology, Beutler E, Lichtman MA, Coller BS, Kipps TJ and Seligsohn U. 6th ed, McGraw-Hill, Inc; New York. 2001; 17-25.

172. Calpin C, Dick P, Poon A, Feldman W. Is bone marrow aspiration needed in acute childhood idiopathic thrombocy topenic purpura to rule out leukemia? Arch Pediatr Adolesc Med 1998; 152: 345-347.

173. Klaassen RJ, Doyle JJ, Krahn MD, Blanchette VS, Naglie G. Initial bone marrow aspiration in childhood idiopathic thrombocytopenia: decision analysis. J Pediatr Hematol Oncol 2001; 23: 511-518.

174. Fleming MD, Kutok JL, Skarin AT. Examination of the bone marrow. In Blood: principles and practice of hematology, Handin RI, Lux SE and Stossel TP. 2nd edition, Lippincott Williams & Wilkins Company; Philadelphia, PA, USA. 2003; 59-80.

175. Harrington WJ, Sprague CC, Minnich V, Moore CV, Aulvin RC, Dubach R. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953; 38: 433-469.

176. Hedge UM, Zuiable A, Ball S, Roter BL. The relative incidence of idiopathic and secondary autoimmune thrombocytopenia: a clinical and serological evaluation in 508 patients. Clin Lab Haematol 1985; 7: 7-16.

177. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997; 126: 307-314.

178. Kelton JG, Murphy WG, Lucarelli A, Garvey-Williams J, Santos A, Meyer R, et al. A prospective comparison of four techniques for measuring platelet-associated IgG. Br J Haematol 1989; 71: 97-105.

179. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.

180. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568-571.

181. Kosugi S, Kurata Y, Tomiyama Y, Tahara T, Kato T, Tadokoro S, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996; 93: 704-706.

182. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87: 4068-4071.

183. Kurata Y, Hayashi S, Kiyoi T, Kosugi S, Kashiwagi H, Honda S, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 2001; 115: 656-664.

184. Coller BS, Kalomiris E, Steinberg M, Scudder LE. Evidence that glycocalicin circulates in normal plasma. J Clin Invest 1984; 73: 794-799.

185. Steinberg MH, Kelton JG, Coller BS. Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. N Engl J Med 1987; 317: 1037-1042.

186. Beer JH, Buchi L, Steiner B. Glycocalicin: a new assay--the normal plasma levels and its potential usefulness in selected diseases. Blood 1994; 83: 691-702.

187. Steffan A, Pradella P, Cordiano I, Girolami A, De Marco L, Fabris F. Glycocalicin in the diagnosis and management of immune thrombocytopenia. Eur J Haematol 1998; 61: 77-83.

188. Houwerzijl EJ, Louwes H, Esselink MT, Smit JW, Vellenga E, de Wolf JT. Increased glycocalicin index and normal thrombopoietin levels in patients with idiopathic thrombocytopenic purpura with a decreased rate of platelet production. Haematologica 2005; 90: 710-711.